Bodisen 8K
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities and Exchange Act of
1934
Date
of
Report (Date of earliest event reported): October 4, 2005
BODISEN
BIOTECH, INC.
(Exact
name of registrant as specified in its charter)
DELAWARE
|
333-99101
|
98-0381367
|
(State
or other jurisdictionof
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer Identification
No.)
|
North
Part of Xinquia Road, Yang Ling
Agricultural
|
|
High-Tech
Industries Demonstration Zone, Yang
Ling, People's Republic of China
|
|
(Address
of principal executive
offices)
|
(Zip
Code)
|
86-29-87074957
(Registrant's
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
|
[
]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
[
]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
|
[
]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item 2.01 Completion of Acquisition or Disposition
of
Assets.
On
October 4, 2005,
Yang
Ling Bodisen Biology Science and Technology Development Company Limited,
a
wholly owned subsidiary of
Bodisen
Biotech, Inc. purchased common stock of Xi Lan Natural Gas Co., Ltd, a Chinese
private company headquartered in the Xi ' An province (“Xi Lan”), for
$2,853,340. This purchase price was calculated on the basis of RMB 2.6 ($0.3206
USD) per share for a total of 8,900,000 shares of common stock. The
purchase of the 8,900,000 shares of common stock represents approximately
12.9%
of Xi Lan’s common stock outstanding.
Item
2.02
Results of Operations and Financial Condition.
On
October 6, 2005, Bodisen Biotech, Inc. issued a press release announcing
record
earnings for the quarter ended September 30, 2005. The press release
is
attached hereto as Exhibit 99.1 and is incorporated herein by reference.
This
Report on Form 8-K is being furnished pursuant to Item 2.02, Results of
Operations and Financial Condition. The information furnished is not deemed
“filed” for purposes of the Securities Exchange Act of 1934, as amended, is not
subject to the liabilities of that section and is not deemed incorporated
by
reference in any filing under the Securities Act of 1933, as
amended.
Item
9.01. Financial Statements an Exhibits.
(c)
Exhibits
Exhibit 99.1 Press Release, dated October 6, 2005
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
BODISEN
BIOTECH, INC |
|
|
|
Date: October
4, 2005 |
By: |
/s/ Qiong
Wang |
|
Qiong
Wang |
|
Chief
Executive Officer |
EXHIBIT
INDEX
Exhibit
Number
|
Description
|
Method
of Filing
|
99.1 |
Press
Release dated October 6, 2005 captioned "Bodisen Biotech, Inc. will
Report
Record 3rd Quarter Earnings, Bodisen makes strategic Investments into
Chinese Natural Gas Company" |
Filed
herewith as
Exhibit
99.1
|